Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained its Buy rating on Zevra Therapeutics but lowered the price target from $24 to $22.
September 18, 2024 | 6:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity has maintained its Buy rating on Zevra Therapeutics but lowered the price target from $24 to $22, indicating a slightly less optimistic outlook.
The maintenance of a Buy rating suggests continued confidence in Zevra Therapeutics, but the lowered price target indicates a slightly less optimistic view on its short-term potential. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100